Abstracts tagged "Lupus"

Abstract Number: 1755 • 2015 ACR/ARHP Annual Meeting
The Lymphotoxin/Megakaryoblastic Leukemia 1/Actin Axis As a Master Regulator of TLR Signaling in Lupus
John D. Mountz¹, Jun Li², Jennie Hamilton³, PingAr Yang⁴, Qi Wu⁵, Bao Luo⁶, Yanna Ding³, Hao Li⁶, David Crossman⁷, Erik Malarkey⁸, Yong Zhou², Yang-Xin Fu⁹ and Hui-Chen Hsu⁵, ¹Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁸Cell, Development, and Integrated Biology, University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Pathology, The University of Chicago, Chicago, IL
Background/Purpose: Marginal zone macrophages (MZMs) of the spleen are essential for rapid and tolerogenic clearance of apoptotic cells (ACs). MZMs are decreased in two…
Abstract Number: 2081 • 2015 ACR/ARHP Annual Meeting
The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program
Melissa T. Flores¹, Roberta Horton¹, Jillian A. Rose¹, Stephen A. Paget² and Michael Lockshin³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York, NY, ³Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: An evaluation was conducted of a monthly hospital-based psychoeducational support group, ongoing since 1985, for people with lupus. Each 2-hour session begins with a…
Abstract Number: 401 • 2015 ACR/ARHP Annual Meeting
Racial and Ethnic Disparities in Depression Diagnosis and Treatment for Adolescents with SLE: Analysis of a National Medicaid Sample
Andrea Knight¹, Ming Xie² and David Mandell³, ¹Pediatrics/Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Center for Mental Health Policy and Services Research, Philadelphia, PA, ³Psychiatry and Pediatrics, University of Pennsylvania, Center for Mental Health Policy and Services Research, Philadelphia, PA
Background/Purpose: Adolescents with systemic lupus erythematosus (SLE) are at high risk for depression. Racial/ethnic minorities are disproportionately affected by SLE, and previous studies suggest a…
Abstract Number: 806 • 2015 ACR/ARHP Annual Meeting
STAT1 Activation Promotes TLR8 Overexpression and Facilitates Mirokine Signaling Via Exosomes Containing a Mir-21 Endogenous Ligand: A Novel Innate Inflammatory Pathway in Systemic Lupus Erythematosus
Giancarlo R. Valiente^1,2, Nicholas A. Young², Lai-Chu Wu^3,4, Jeffrey Hampton⁵, Mary Severin⁶, Amy Lovett-Racke⁶ and Wael N. Jarjour⁷, ¹Medical Scientist Training Program, The Ohio State University College of Medicine, Columbus, OH, ²Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, ⁵Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, ⁷Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: The adaptive arm of the immune system plays a significant role in the pathophysiology of Systemic Lupus Erythematosus (SLE). However, recent studies suggest that…
Abstract Number: 1764 • 2015 ACR/ARHP Annual Meeting
Type 1 Interferon in the Skin Stimulated By Ultraviolet B Light Generates Immune Suppression Mediated By Idoleamine 2,3-Dioxygenase 1
Clayton Sontheimer¹ and Keith B. Elkon², ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions show local Type 1 Interferon (IFN-I) profiles similar…
Abstract Number: 2083 • 2015 ACR/ARHP Annual Meeting
Predictors of Health Perceptions Among Women with Lupus
Patricia P. Katz¹, Eliza Chakravarty², Robert S. Katz³ and Kaleb Michaud⁴, ¹Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Rush University Medical Center, Chicago, IL, ⁴Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Health perceptions, such as self-rated health, have been shown to predict multiple adverse health outcomes and to have a strong socioeconomic status (SES) gradient. …
Abstract Number: 402 • 2015 ACR/ARHP Annual Meeting
Predicting Area Under the Curve of Mycophenolate Mofetil in Childhood-Onset Systemic Lupus Erythematosus
Roberto Ezequiel Borgia¹, Masanobu Takeuchi², Deborah M. Levy³, Shinya Ito‎⁴ and Earl Silverman⁵, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Program of Physiology & Experimental Medicine, Peter Gilgan Centre For Research and Learning (PGCRL), The Hospital for Sick Children, Toronto ON, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴3Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children Toronto ON, Toronto, ON, Canada, ⁵Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Mycophenolate mofetil (MMF) is an immunosuppressive drug used off-label for the treatment of childhood-onset systemic lupus erythematosus (cSLE). Therapeutic drug monitoring (TDM) of MMF’s…
Abstract Number: 814 • 2015 ACR/ARHP Annual Meeting
Lupus Drives Atherosclerosis through CD4+CXCR3+ T Cells and Plasmacytoid Dendritic Cells
Tiphaine Goulenok¹, Marc Clement², Nicolas Charles³, Brigitte Escoubet⁴, Marie-Paule Chauveheid⁵, Thomas Papo⁶ and Karim Sacre⁷, ¹University Paris Diderot - APHP - Bichat Hospital, aris, France, ²University Paris Diderot - INSERM U1148, Paris, France, ³INSERM U699, Paris, France, ⁴University Paris- Diderot - APHP - Hôpital Bichat, Paris, France, ⁵Internal Medicine, Bichat-Claude Bernard Hospital, University Paris-7, Paris, France, ⁶CHU Bichat, Paris, France, ⁷Internal Medicine, University Paris-7, INSERM U1149, APHP, Bichat Hospital, Paris, France
Background/Purpose: Accelerated atherosclerosis is the leading cause of death in systemic lupus erythematosus (SLE). How SLE promotes accelerated atherosclerosis remains elusive. The purpose of this…
Abstract Number: 1777 • 2015 ACR/ARHP Annual Meeting
Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
Li Chun Wang¹, Stuart Perper¹, Kimberly Black¹, Regina Mario¹, Candace Graff^2,3, Dawna Hartman³, Andrew Souers⁴, Steven Elmore⁴ and Lisa Olson^1,3, ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. We report here that continuous daily treatment with 30mpk venetoclax…
Abstract Number: 2221 • 2015 ACR/ARHP Annual Meeting
Engaging Learners in Lupus Education with Pivot (Practice Improvement using Virtual Online Training), a Novel, Digital Case-Based Curriculum
Karen Law¹, Michelle Lin², Sheryl McCalla³ and Maria Dall'Era⁴, ¹Emory University School of Medicine, Atlanta, GA, ²Emergency Medicine, UCSF, San Francisco, CA, ³American College of Rheumatology, Atlanta, GA, ⁴University of California San Francisco School of Medicine, San Francisco, CA
Background/Purpose: Lupus is one of the prototypic rheumatic diseases, yet only a small amount of time in medical school curricula is devoted to lupus-specific education.…
Abstract Number: 422 • 2015 ACR/ARHP Annual Meeting
Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort
Tamar Rubinstein^1,2, Dawn Wahezi^1,2, Jay Mehta^3,4, Norman Ilowite^3,5, Debbie Rybak⁶, Jordan Brodsky⁶, Nicole Jordan⁶, Ruth Stein^5,7 and Chaim Putterman⁶, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁴Division of Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁷Pediatrics, Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: While mood disorder, most commonly manifesting as depression and anxiety symptoms, is often reported in pediatric lupus patients, prevalence rates vary widely. Many published…
Abstract Number: 815 • 2015 ACR/ARHP Annual Meeting
Lys63-Polyubiquitination By the E3 Ligase Casitas B-Lineage Lymphoma-b Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín¹, Jorge Alcocer-Varela¹, Jorge Romo-Tena¹, Ana Barrera-Vargas¹ and Javier Merayo-Chalico², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The interplay between effector and regulatory T cells (Tregs) is a key element among peripheral tolerance mechanisms in Systemic Lupus Erythematosus (SLE). Resistance to…
Abstract Number: 1779 • 2015 ACR/ARHP Annual Meeting
Characterization of Anti-Nuclear Antibody (ANA) Signatures in Murine Models of Lupus Using Genalyte Maverick Technology
Jacqueline Loud¹, Stuart Perper², Rachel Twomey² and Stephen Clarke², ¹Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Pharmacology, Abbvie Bioresearch Center Inc., Worcester, MA
Background/Purpose: Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are autoimmune diseases characterized by circulating antibodies to nuclear self-antigens, including reactivities to double-stranded DNA, RNP…
Abstract Number: 2512 • 2015 ACR/ARHP Annual Meeting
Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women
Yuli McCann¹, Meredith Barnes¹ and Grant Hughes², ¹Medicine, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Female sex steroids are important modulators of autoimmunity. Estrogen appears to favor the development of lupus autoimmunity via activation of adaptive and innate immune…
Abstract Number: 423 • 2015 ACR/ARHP Annual Meeting
Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database
Breanna Beltz¹, Mohammad Shah², Mary Toth³ and Moussa El-Hallak⁴, ¹Hiram College, Akron, OH, ²Patient Safety and Quality Services, Akron Children's Hospital, Akron, OH, ³Rheumatology, Akron Children's Hospital, Akron, OH, ⁴Dept of Pediatric Rheumatology, Akron Children's Hospital, Akron, OH
Background/Purpose: Early hospital readmission is emerging as an indicator of care quality. The reported 30-day hospital readmission (30-DHR) rate for pediatric patients is 6.5%. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].